drugset
drugset / Trial / NCT01221519

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01221519 ↗

Phase 1 Completed 20 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the relative bioavailability by measuring the extent and rate of absorption of different tablet formulations of AZD1656 in T2DM patients.

Timeline

Start
2010-09
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule — —

Indications

hyperglycemia type 2 diabetes mellitus